In July, I had an in-depth INTERVIEW with Chris Lustrino, founder & CEO of Kingscrowd.com, a company specializing in equity crowdfunding analysis, ratings and news.
Kingscrowd released an INDEPENDENT ANALYST REPORT on Nemucore giving us ‘BUY’ rating and ‘DEAL TO WATCH’ designation.
Anyone involved with Nemucore Medical Innovations knows, we are ALL IN on attracting new stakeholder to our mission to defeat Acute Myeloid Leukemia (AML) by utilizing the most advanced financing options to reach motivated, like-minded investors. We believe the newfound freedoms of the JOBS act created a once-in-a-lifetime opportunity for investors and entrepreneurs to transform lives of patients suffering with disease that today may have few or no therapies available. We're proud of the role Nemucore is playing to pioneer this new frontier for biopharmaceutical companies to create solutions for unmet clinical needs like AML.
Chris shares a similarly bullish view on the disruptive potential of JOBS act and luckily for us he developed sophisticated knowledge of biopharmaceutical industry while performing private equity diligence at a leading consultant firm. Chris is working to establish Kingscrowd as a next generation "Morningstar" that provides independent research and education for investors in the space. It's an important role in the equity crowdfunding ecosystem, and one we're pleased to see a responsible company like Kingscrowd filling.
Given the research he has done and his unique expertise and perspective on equity crowdfunding, our team is thankful for the validation this knowledgeable report provides. It illuminates the effort required to create a significant opportunity for our growing number of stakeholders.
And If you want to take Chris’s recommendation, our OFFERING will be open for a few more weeks at https://wefunder.com/nemucore.medical.innovations.inc !
Privacy: We won’t share your data, or post to your wall, without your permission.
Already have a Wefunder account? Login
Don't have a Wefunder account? Signup